Kelly is the Vice President and Program Lead for the Gaucher disease franchise. She brings to the role extensive experience with leading program teams for early and late-stage programs.

Prior to joining AVROBIO, Kelly served as Vice President of Program Management and Program Lead for the SRF388 program at Surface Oncology, a program testing a fully human anti-IL-27 antibody designed to inhibit the activity of IL-27, an immunosuppressive cytokine. Prior to that, she held roles with increasing responsibility in Program and Project Management at Amag Pharmaceuticals, Merck, Radius Health, Sanofi and Genzyme. Kelly earned her bachelor’s degree in Biology and Human Development from Colby College.

She is currently pursuing a Master’s of Science in Immunology at Drexel University Medical College.